Extended Ophthalmoscopy
Customize your policy alerts
Sign up for Aetna Policy 0767 alerts
Get alerted when Policy 0767 changes without checking for updates manually.
Monitor payer policy activity
Policy governing medical necessity, coverage, and documentation requirements for extended ophthalmoscopy (detailed retinal drawing with interpretation) for evaluation of the posterior segment of the eye; applies to Aetna members and providers submitting claims to Aetna.
No material clinical or coverage changes in this revision.
Coverage Criteria
Medical Necessity Indications
Covered when ANY of the following indications are present (extended ophthalmoscopy with a detailed retinal drawing is medically necessary following routine ophthalmoscopy):
Must be based on routine ophthalmoscopy findings indicating need for more detailed study; extended ophthalmoscopy must add information not available from standard evaluation and should affect the treatment plan. Repeat exams are medically necessary only when signs, symptoms or condition change.
Experimental / Investigational (Not established effectiveness)
Considered experimental and investigational for the following indications:
Listed examples where effectiveness has not been established and use is considered experimental/investigational.
Extended ophthalmoscopy is considered not medically necessary when the initial routine ophthalmoscopy showed normal clinical findings. The policy lists specific diagnostic examples and ICD-10 codes that are not covered for the indications in this Clinical Policy Bulletin, including conditions such as sickle-cell disease, optic neuritis, Noonan's syndrome, and other neurodegenerative or congenital conditions referenced in the ICD-10 lists.
When submitting claims, ensure the documented routine ophthalmoscopy findings support the need for extended ophthalmoscopy; absence of abnormal findings on the initial exam is a basis for denial per this policy.
Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and do not constitute a contract or an offer of coverage. They provide a partial, general description of plan or program benefits and may be updated. Participating providers remain responsible for treatment decisions and should consult the member's benefit plan and the Clinical Policy Bulletin Notes for any administrative details or coverage determinations.
Repeated extended ophthalmoscopy performed at each visit without any documented change in signs, symptoms, or clinical condition may be considered not medically necessary. Frequency of the service should be driven by medical necessity and whether sequential drawings will affect management.
Documentation supporting repeat exams must show interval change that would directly affect the treatment plan; otherwise repetition of an adequate prior drawing is not justified under this policy.
Coding
| 92201 | Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation and report, unilateral or bilateral. |
| 92202 | Ophthalmoscopy, extended; with drawing of optic nerve or macula (eg, for glaucoma, macular pathology, tumor) with interpretation and report, unilateral or bilateral. |
| B20 | Human immunodeficiency virus [HIV] disease |
| C69.20 - C69.32 | Malignant neoplasm of retina or choroid |
| D31.30 - D31.32 | Benign neoplasm of choroid [evaluation of choroidal nevus for malignant transformation] |
| E08.311 - E08.3559 | Diabetes mellitus with ophthalmic complications (various subcodes listed) |
| E09.311 - E09.39 | Drug or chemical induced diabetes mellitus (with ophthalmic complications) |
| E10.311 - E10.39 | Diabetes mellitus with ophthalmic complications (type 1) |
| E11.311 - E11.39 | Diabetes mellitus with ophthalmic complications (type 2) |
| E13.311 - E13.39 | Diabetes mellitus due to underlying condition with ophthalmic complications |
| G45.3 | Amaurosis fugax |
| H05.50 - H05.53 | Retained (old) foreign body following penetrating wound of orbit |
| D18.09 | Hemangioma of other sites [retina] |
| D57.00 - D57.1 | Sickle-cell disease |
| D76.3 | Other histiocytosis syndromes [juvenile xanthogranuloma] |
| G10 | Huntington's chorea |
| G11.1 | Early-onset cerebellar ataxia [Friedreich's ataxia] |
| G12.0 - G12.9 | Spinal muscular atrophy and related syndromes |
| G20 | Parkinson's disease |
| G23.0 - G23.9 | Other degenerative diseases of basal ganglia |
| G30.0 - G30.9 | Alzheimer's disease |
| G31.83 | Dementia with Lewy bodies |
| L25466 | Medicare LCD reference for posterior segment imaging (extended ophthalmoscopy and fundus photography) |
Provider Actions & Requirements
Prior authorization requirement for CPT 92201 / 92202
CPT codes 92201 and 92202 are covered only when the policy selection criteria (medical necessity indications) are met — i.e., extended ophthalmoscopy is medically necessary for one or more listed indications following routine ophthalmoscopy.
Refer to Clinical Policy Bulletin for prior authorization guidance
Consult the Clinical Policy Bulletin notes and the policy review history for any prior authorization details and administrative updates related to code-level requirements.
- Refer to the Clinical Policy Bulletin Notes link for administrative details.
- Review the policy history (last review and effective dates) for recent changes that may affect prior authorization.
Document medical necessity when billing extended ophthalmoscopy
Ensure documentation demonstrates that extended ophthalmoscopy was medically necessary for the member’s condition and that the service added information not available from standard evaluation or prior imaging.
- Medical necessity must be based on routine ophthalmoscopy findings indicating need for more detailed study.
- Do not bill extended ophthalmoscopy solely to confirm information already available from other tests.
Check Clinical Policy Bulletin for administrative updates
Providers should consult the Clinical Policy Bulletin for administrative updates and note that the bulletin may be updated; maintain current awareness of any changes that could affect coverage or submission requirements.
- Clinical Policy Bulletins may be updated and are the source for administrative details.
- Keep documentation and billing practices aligned with the most recent bulletin version.
Required documentation: detailed retinal drawing and report
Include a detailed retinal drawing (disc, macula or periphery) with interpretation and plan; the drawing must be anatomically specific, clearly labeled, and of sufficient size — usually no less than 2.5 inches in diameter.
- Drawing must represent normal and abnormal findings and include ancillary cup-to-disc drawings when defining optic nerve changes.
- Color coding is optional but if not used, a descriptive anatomy/pathology narrative is required.
Clinical justification must show additive information
Document how extended ophthalmoscopy provided additive clinical information not available from standard evaluation or other imaging and how it affected the treatment plan.
- Extended ophthalmoscopy must add information that will demonstrably affect the treatment plan.
- When other imaging (e.g., fundus photography, fluorescein angiography, OCT, ultrasound) has been performed, document the reasonable expectation of additive non-duplicative information.
Use Clinical Policy Bulletin for policy materials and updates
Providers should consult the Clinical Policy Bulletin Notes for administrative details and potential updates to policy materials; the bulletin is the reference for administering plan benefits.
- Clinical Policy Bulletins are available via the policy’s Additional Information section.
- Confirm bulletin updates before submitting claims or prior authorization requests.
Denial risk for repeat exams without change
Repeatedly performing extended ophthalmoscopy at each visit without documented change in signs, symptoms, or condition risks denial as not medically necessary.
- Frequency of service must be based on medical necessity and diagnosis; sequential drawings are appropriate only when they document clinically significant change.
- If there is no change, the service may be considered not medically necessary.
Denial risk when initial routine exam is normal
Extended ophthalmoscopy is considered not medically necessary when the initial routine ophthalmoscopy showed normal clinical findings; billing in that circumstance risks denial.
- Ensure routine ophthalmoscopy findings indicate need for extended study before documenting and billing extended ophthalmoscopy.
- If initial routine exam was normal, do not submit extended ophthalmoscopy as medically necessary.
Administrative/legal note about Clinical Policy Bulletins
Clinical Policy Bulletins are developed to assist in administering plan benefits and do not constitute offers of coverage or medical advice; providers remain responsible for treatment decisions and should note that the bulletin may be updated.
- The bulletin contains only a partial description of benefits and is not a contract.
- Providers are independent and responsible for medical advice and treatment decisions.
Background
Extended ophthalmoscopy is an examination of the posterior segment of the eye that provides a more detailed, documented view than routine ophthalmoscopy. It typically involves pharmacologic dilation and may use indirect ophthalmoscopy, scleral depression, or contact lens biomicroscopy to evaluate the optic disc, macula, retina, choroid and related structures.
This procedure includes a detailed retinal drawing with an interpretation and plan; the drawing should be anatomically specific, clearly labeled and of sufficient size (usually no less than 2.5 inches in diameter) to represent clinically significant findings that cannot be adequately communicated by text or other imaging alone. Extended ophthalmoscopy must add information not available from standard evaluation or other imaging studies and be expected to demonstrably affect the treatment plan.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.